We read with interest the study “Molnupiravir for the treatment of COVID-19 in
immunocompromised participants: efficacy, safety, and virology results from the phase 3 …

We read with great interest the review article by Gary et al., in which they raised several
concerns about the use of molnupiravir in the treatment of patients with COVID-19. 1 At the …

Purpose Immunocompromised patients have a potentially increased risk for progression to
severe COVID-19 and prolonged replication of SARS-CoV-2. This post hoc analysis …

We thank Drs Kow, Ramachandram and Hasan for their interest in our review and their
knowledgeable comments. 1 We agree with your thoughtful view that the most important …

We read with great interest the systematic review and meta-analysis by Sun et al. 1 titled
'Molnupiravir for the treatment of non-severe COVID-19: a systematic review and meta …

We were greatly intrigued by the systematic review and meta-analysis conducted by Sun et
al., 1 which investigated the efficacy of molnupiravir in patients with COVID-19. As we find …

Background New treatments are needed to reduce the risk of progression of coronavirus
disease 2019 (Covid-19). Molnupiravir is an oral, small-molecule antiviral prodrug that is …

Background Paxlovid has been shown to reduce the risk of progression
(hospitalization/death) by 88% as compared to placebo, while molnupiravir reduced that risk …

Background Molnupiravir is an oral prodrug of β-d-N4-hydroxycytidine, active against SARS-
CoV-2 in vitro and in animal models. We report data from the phase 2 component of MOVe …

Background The role of molnupiravir for coronavirus disease 2019 (COVID-19) treatment is
unclear. Methods We conducted a systematic review until 1 November 2022 searching for …